These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18549347)

  • 61. Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study.
    Geroin C; Di Vico IA; Squintani G; Segatti A; Bovi T; Tinazzi M
    J Neural Transm (Vienna); 2020 Aug; 127(8):1143-1152. PubMed ID: 32572581
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
    Tsuboi Y; Koebis M; Kogo Y; Ishida T; Suzuki I; Nomoto M; Hattori N
    J Neurol Sci; 2021 Oct; 429():118070. PubMed ID: 34509801
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study.
    Rinaldi D; Bianchini E; Sforza M; Alborghetti M; Galli S; Salvetti M; Giovannelli M; Pontieri FE
    Aging Clin Exp Res; 2021 Jun; 33(6):1689-1692. PubMed ID: 32681474
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Qureshi AR; Rana AQ; Malik SH; Rizvi SFH; Akhter S; Vannabouathong C; Sarfraz Z; Rana R
    Neuroepidemiology; 2018; 51(3-4):190-206. PubMed ID: 30153669
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Investigational agents in the treatment of Parkinson's disease: focus on safinamide.
    Malek NM; Grosset DG
    J Exp Pharmacol; 2012; 4():85-90. PubMed ID: 27186120
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Current Status of Pain Management in Parkinson's Disease.
    Karnik V; Farcy N; Zamorano C; Bruno V
    Can J Neurol Sci; 2020 May; 47(3):336-343. PubMed ID: 31928559
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
    Liguori C; Stefani A; Ruffini R; Mercuri NB; Pierantozzi M
    Parkinsonism Relat Disord; 2018 Dec; 57():80-81. PubMed ID: 30006034
    [No Abstract]   [Full Text] [Related]  

  • 69. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.
    Faulkner MA
    Expert Opin Drug Saf; 2014 Aug; 13(8):1055-69. PubMed ID: 24962891
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
    Müller T; Riederer P; Grünblatt E
    Clin Neuropharmacol; 2017; 40(5):208-211. PubMed ID: 28682929
    [TBL] [Abstract][Full Text] [Related]  

  • 71. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
    Fox SH; Katzenschlager R; Lim SY; Barton B; de Bie RMA; Seppi K; Coelho M; Sampaio C;
    Mov Disord; 2018 Aug; 33(8):1248-1266. PubMed ID: 29570866
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safinamide: an add-on treatment for managing Parkinson's disease.
    Müller T
    Clin Pharmacol; 2018; 10():31-41. PubMed ID: 29670409
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
    Grégoire L; Jourdain VA; Townsend M; Roach A; Di Paolo T
    Parkinsonism Relat Disord; 2013 May; 19(5):508-14. PubMed ID: 23402994
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Emerging approaches in Parkinson's disease - adjunctive role of safinamide.
    Müller T
    Ther Clin Risk Manag; 2016; 12():1151-60. PubMed ID: 27536120
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
    Labandeira CM; Alonso Losada MG; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz González JM; Gonzalez Palmás MJ; Martínez Miró C; Santos García D
    Adv Ther; 2021 Oct; 38(10):5398-5411. PubMed ID: 34523075
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Management of Parkinson׳s disease: Current and future pharmacotherapy.
    Kakkar AK; Dahiya N
    Eur J Pharmacol; 2015 Mar; 750():74-81. PubMed ID: 25637088
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.
    Bette S; Shpiner DS; Singer C; Moore H
    Ther Clin Risk Manag; 2018; 14():1737-1745. PubMed ID: 30271159
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of high doses of safinamide in advanced Parkinson disease.
    Rodríguez-Jorge F; Beltrán-Corbellini Á; Chico-García JL; Parra-Díaz P; Baena-Álvarez B; Pagonabarraga J; Pérez-Torre P; Pareés I; López-Sendón JL; Martínez-Castrillo JC; Alonso-Cánovas A
    Parkinsonism Relat Disord; 2022 Apr; 97():73-74. PubMed ID: 35344893
    [No Abstract]   [Full Text] [Related]  

  • 80. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.